Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 01 2020
revised: 18 04 2020
accepted: 18 05 2020
pubmed: 9 6 2020
medline: 5 11 2020
entrez: 9 6 2020
Statut: ppublish

Résumé

Myeloid neoplasms (MN) are usually sporadic late-onset cancers; nevertheless, growing evidence suggests that ∼5% of the cases could emerge as a consequence of inherited predisposition. Distinguishing somatic from germline variants is of vital importance, in order to establish an appropriate individualized management and counsel the patients and their relatives. Since many of the genes associated with myeloid neoplasm germline predisposition (MNGP) are also affected in sporadic MN, we intended to design a strategy to identify potentially inherited variants in a tumor only NGS panel in a cohort of 299 patients with a variety of MN. We considered as indicative of potential inherited origin, variants detected in BM sample at a ∼50% VAF classified as pathogenic, likely pathogenic or of unknown significance detected in MNGP-related genes. A total of 104 suspicious variants from 90 patients were filtered-in in tumor samples. Mutational patterns, follow-up data, and sequencing of a range of non-myeloid tissues were used for narrowing down the list of suspicious variants, and ultimately discriminate their nature. Our data supports the importance of considering variants found upon tumor-only sequencing as potentially of germline origin, and we offer a pipeline to define the nature of the variants.

Identifiants

pubmed: 32512379
pii: S0145-2126(20)30091-6
doi: 10.1016/j.leukres.2020.106386
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106386

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Almudena Aguilera-Diaz (A)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

María José Larrayoz (MJ)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Sara Palomino-Echeverría (S)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Iria Vazquez (I)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Beñat Ariceta (B)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Amagoia Mañú (A)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Zuriñe Blasco-Iturri (Z)

Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Teresa Bernal Del Castillo (T)

Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Matxalen Olivares Salaverri (M)

Hematology Department, Hospital Universitario de Galdakao, Galdakao, Spain.

Maria Teresa Olave Rubio (MT)

Hematology Department, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain.

Jose Rifon-Roca (J)

Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain.

Ana Alfonso-Pierola (A)

Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain.

Felipe Prosper (F)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain.

Marta Fernandez-Mercado (M)

Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain. Electronic address: mfmercado@unav.es.

María José Calasanz (MJ)

Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain; Scientific Co-Director of CIMA LAB Diagnostics, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH